Although the anti-inflammatory effects of prebiotics in IBD patients remains controversial, co-treatment with PHI may be an interesting strategy, which would combine the regenerative potential of HIF1α activation with stimulation of growth of commensal bacteria. The gene discussed is HIF1A; the disease is irritable bowel syndrome.